ProCE Banner Activity

LEAP-002: Placebo-Controlled Phase III Trial of Lenvatinib ± Pembrolizumab as First-line Therapy for Advanced HCC

Slideset Download
Conference Coverage
Primary results from the phase III LEAP-002 study showed that first-line treatment with lenvatinib plus pembrolizumab was not superior to lenvatinib plus placebo in patients with advanced hepatocellular carcinoma.

Released: September 19, 2022

Expiration: September 18, 2023


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from


Bristol Myers Squibb

Exelixis, Inc.

Gilead Sciences, Inc.

Merck Sharp & Dohme Corp.